Aquaporin lowers revenue guidance for 2025, but maintains EBITDA guidance, and initiates strategic review
Company announcement
No. 15/2025
Inside information
Nymøllevej 78
DK-2800 Kongens Lyngby
aquaporin.com
Company registration no.: DK28315694
The updated revenue guidance is adjusted to
The revised revenue guidance is the result of a lower inflow of orders in 2025 as well as a delay in certain orders. The updated range includes already-recognized revenue, firm commitments, and a larger soft commitment. In line with previous years, the Company expects the largest part of the revenue to materialize in the second half of 2025.
"Although the run-up to materialize orders in 2025 has been slower than expected, I believe
To ensure sufficient capital in the years following 2025, and to support further growth, the Company has initiated a strategic review to explore multiple opportunities to raise capital, including equity or debt financing and/or through a strategic transaction or partnership.
The Company will publish its Half-Year Interim Report 2025 on
For further information, please contact:
+45 53 55 55 19, investorrelations@aquaporin.com
About
Forward-looking statements
Matters discussed in this report may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and that can be identified by words such as "believe", "expect", "anticipate", "intend", "estimate", "will", "may", "continue", "should", and similar expressions, as well as other statements regarding future events or prospects. Specifically, this report includes information with respect to projections, estimates, and targets that also constitute forward-looking statements. The forward-looking statements in this report are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies, and other important factors which are difficult or impossible to predict and are beyond its control. Such risks, uncertainties, and other important factors include, among others: Limited experience in commercialization of the Company's products, failure to successfully implement strategies, dependence on third parties for manufacturing certain product components and the supply of certain raw materials, manufacturing disruptions, strategic collaboration, protection of the Company's intellectual property rights and other risks disclosed in
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
15-2025 |
|
https://news.cision.com/aquaporin-a-s/i/071119-aquaporin-00867-sh,c3460047 |
071119- |
View original content:https://www.prnewswire.co.uk/news-releases/aquaporin-lowers-revenue-guidance-for-2025-but-maintains-ebitda-guidance-and-initiates-strategic-review-302526782.html
